Medicare to Cover Lilly’s Orforglipron Immediately, Enabling Q2 Full Launch
Eli Lilly CEO Dave Ricks expects Medicare to cover its experimental weight loss pill orforglipron immediately after its launch later this year, potentially broadening access beyond current cash-pay patients. The company plans a full Q2 rollout coinciding with the first-ever Medicare obesity drug coverage under recent Trump pricing agreements.
1. CEO Highlights Medicare Coverage as a Major Catalyst
In an exclusive CNBC interview, Eli Lilly CEO Dave Ricks emphasized that forthcoming Medicare coverage of obesity drugs—scheduled to commence later this year under recent drug-pricing agreements—will be a pivotal driver for the company’s experimental GLP-1 pill, orforglipron. Ricks stated that Lilly anticipates coverage “immediately following that launch,” enabling broader patient access and reducing out-of-pocket costs. He noted that early adopters of competitor Novo Nordisk’s Wegovy have been predominantly new to GLP-1 treatments, expanding the addressable market. Lilly is preparing for a full commercial rollout in Q2, confident that its pill’s efficacy and convenient oral formulation will secure significant share in a market projected to exceed $30 billion by 2027.
2. $3.5 Billion Pennsylvania Facility to Boost Obesity Drug Capacity
Eli Lilly announced plans to invest $3.5 billion in a new manufacturing plant in Lehigh Valley, Pennsylvania, with construction slated to begin this year and operations targeted for 2031. The site will produce next-generation obesity injectables, including retatrutide—an experimental candidate that has delivered the highest weight-loss results in late-stage trials to date. This facility marks Lilly’s fourth domestic expansion since 2020, contributing to a cumulative $50 billion in U.S. manufacturing investments. Upon completion, the plant is expected to create 850 permanent jobs and 2,000 construction roles, reinforcing Lilly’s strategy to secure supply for its leading GLP-1 portfolio following prior shortages.
3. FDA Delay on Orforglipron Decision Extends Uncertainty
The FDA has postponed its target action date for orforglipron by nearly two weeks, moving the decision into Q2. While this delay is procedural, it extends the timeline for the drug’s market entry and defers potential revenue recognition that analysts estimate could reach $5 billion annually by 2028. Investors and management had anticipated a regulatory verdict in the first quarter, aligning with the Q2 launch preparations. Lilly reiterated its confidence in the clinical profile of orforglipron, citing consistent weight-loss outcomes and a favorable safety record in phase III studies encompassing over 3,500 participants.